Abstract:Tumor-associated macrophages (TAMs) are an abundant immune cell population in most cancers that support tumor progression through their immunosuppressive effects. We discovered that TAMs express the pattern recognition receptor Dectin-2 (Clec4n/CLEC6A), an activating C-type lectin receptor (CLR) that binds to high-mannose glycans on fungi and other microbes and induces protective immune responses against infectious disease. Dectin-2 is selectively expressed by myeloid cells, and upon ligation mediates enhanced phagocytosis, antigen processing and presentation, and proinflammatory cytokine production. Given these properties, we evaluated the therapeutic potential of targeting Dectin-2 using naturally derived ligands. We also generated human Dectin-2-targeted agonistic antibodies capable of robustly activating immunosuppressive ”M2” or TAM-like macrophages.Dectin-2 expression was assessed by flow cytometry, immunohistochemistry, and using public databases. Mouse and human monocytes were differentiated into macrophages using recombinant cytokines or tumor-conditioned media, and stimulation was measured following overnight incubation with Dectin-2 ligands or antibodies. Mouse tumor cell lines were implanted into syngeneic hosts and mice were treated with mannan derived from S. cerevisiae via IT or IV administration.Dectin-2 gene expression is minimal in normal human tissues but elevated across many tumor types, including breast, colon, lung, and kidney cancers. Dectin-2 is strongly expressed by macrophages differentiated in vitro and on primary TAMs. The fungal Dectin-2 ligand mannan stimulated proinflammatory cytokine production (e.g. TNFalpha) and costimulatory molecule expression (e.g. CD86) by macrophages in a Dectin-2-dependent manner. Treatment of tumor-bearing mice with mannan mediated tumor regression in multiple syngeneic tumor models, with high rates of tumor clearance in the MB49 bladder cancer model. These effects were Dectin-2 dependent, as efficacy was not observed when a Dectin-2-blocking antibody was co-administered or in knockout mice lacking Dectin-2 signaling components. Furthermore, depletion of either macrophages or T cells impaired efficacy, suggesting that Dectin-2-stimulated TAMs augment anti-tumor T cell responses. Based on these data, we developed novel Dectin-2 targeted agonist antibodies capable of activating human ”M2” or TAM-like macrophages in vitro to produce an array of proinflammatory cytokines and chemokines akin to tumor-destructive ”M1” macrophages.The data presented demonstrate the therapeutic potential of targeting Dectin-2 using natural ligands or agonistic antibodies as a novel pan-cancer approach for myeloid cell-directed tumor immunotherapy.All animal studies were performed in accordance with Institutional Animal Care and Use Committee (IACUC)-approved protocols.

Exploration of the Dual Role of Dectin-1 in Tumor Development and Its Therapeutic Potential

Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer

Tumor Immune Checkpoints and Their Associated Inhibitors

The role of dectin-1 in health and disease

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy

C-type lectin receptor Dectin-1 blockade on tumour-associated macrophages improves anti-PD-1 efficacy in gastric cancer

Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways

Pancreatic ductal adenocarcinoma cells reshape the immune microenvironment: Molecular mechanisms and therapeutic targets

PD-1 and its ligands are important immune checkpoints in cancer

862 Dectin-2, a novel target for tumor macrophage reprogramming in cancer immunotherapy

Dectin-1 Signaling Update: New Perspectives for Trained Immunity

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy.

MyD88 and Its Inhibitors in Cancer: Prospects and Challenges

Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1

PD-1 regulation in immune homeostasis and immunotherapy

PD-1/PD-L1 pathway: current researches in cancer.

The role of dendritic cells in cancer immunity and therapeutic strategies

The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications

Multifaceted roles of PD‐1 in tumorigenesis: From immune checkpoint to tumor cell‐intrinsic function

Roles of DEPDC1 in various types of cancer (Review)

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses